APTX Aptinyx Inc.
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders.
$0.50
As of 05/26/2022 IEX book CBOE book
Security Information
Category1:
US EquityCategory2:
Common stocksCategory3:
Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation: USA
IPO date: 06/21/2018
Outstanding shares: 67,715,718
Average volume: 323,791
Market cap: $36,857,665
Current dividend yield: 0.00%
All SEC filings:
SEC Edgar Online
Quarterly filings:
10-Q
Annual filings:
10-K
Sedol:
Valuation (See tab for details)
PE ratio: -0.90
PB ratio: 0.48
PS ratio: 7.54
Return on equity: -103.87%
Net income %: -1,585.97%